HCV-2

GPTKB entity

Statements (48)
Predicate Object
gptkbp:instance_of gptkb:healthcare_organization
gptkbp:bfsLayer 4
gptkbp:bfsParent gptkb:Hepacivirus
gptkbp:associated_with Liver cancer
Liver cirrhosis
Chronic liver disease
gptkbp:caused_by gptkb:healthcare_organization
gptkbp:duration 8 to 12 weeks
gptkbp:genetic_diversity 2
Higher genetic diversity than HCV-1
gptkbp:healthcare Requires ongoing surveillance
Significant in endemic regions
https://www.w3.org/2000/01/rdf-schema#label HCV-2
gptkbp:is_a gptkb:virus
gptkbp:is_popular_in Lower than HCV-1
gptkbp:is_recognized_by 1990s
gptkbp:is_vulnerable_to No vaccine available
gptkbp:region gptkb:Southeast_Asia
West Africa
gptkbp:research_focus Vaccine development
Genetic studies
Epidemiological studies
Improved treatment regimens
Understanding viral pathogenesis
gptkbp:risk_factor Blood transfusions
Intravenous drug use
Sexual transmission
Tattooing with unsterile equipment
Unsterile medical equipment
gptkbp:social_responsibility Blood test
HCV antibody test
HCVRNA test
Can lead to chronic hepatitis
Can lead to extrahepatic manifestations
Can lead to liver failure
Less common than HCV-1 globally
More prevalent in certain populations
gptkbp:symptoms Fatigue
Abdominal pain
Jaundice
gptkbp:transmission gptkb:healthcare_organization
gptkbp:treatment Antiviral therapy
Direct-acting antivirals
Higher than 90% with modern therapies
Interferon-based therapy
gptkbp:type_of 2a
2b
2c